NEW YORK (GenomeWeb News) – Caris Life Sciences today announced a distribution deal with IPS Genomix to provide patients access to Caris' tumor profiling service in certain Middle Eastern and African markets.
Nancy Kelley has stepped down from her post as founding executive director of the New York Genome Center. Kelley had been the driving force behind the center's creation and last November had also taken on the role of chief operating officer.
Caris Life Sciences has added next-generation sequencing on the Illumina MiSeq to the array of molecular tumor profiling technologies it uses to help guide cancer therapy, including fluorescence in situ hybridization, PCR, and immunohistochemistry.
Enzo Begins Marketing Dx Test for Early Lung Cancer Detection
Enzo Clinical Labs this week launched a diagnostic test to help oncologists detect lung cancer early and gauge which patients are at heightened risk for disease progression.
The company plans two new versions of its MyPRS test later this year, including a pharmacogenomic enhancement called MyPRS RX and a version called MyPRS Plus that will perform myeloma subgroup analysis.